IP Library Granted Patent US 7,645,801
Granted Patent B2
US 7,645,801 · App. 11/749,732 · Granted Jan 12, 2010

Reduced irritant enema for treatment of inflammatory bowel disease (IBD)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,645,801
App. No.
11/749,732
Granted
Jan 12, 2010
Kind
B2
Abstract

The present invention comprises packaged enemas for the treatment of Inflammatory Bowel Disease (IBD), having substantially pure 5-ASA as the active ingredient, with a liquid carrier medium having a material avoidance of bowel irritant substances, such as anti-oxidants for the 5-ASA active ingredient, including such sulfites as potassium metabisulfite, for example, and contained within a sealed and substantially oxygen-free barrier package, which may preferably be formed of a foil/polymer laminate, and which package contains or otherwise includes an oxygen scavenger, such as a an oxygen scavenging sachet.

Claims (22)

1. A packaged enema for the treatment of inflammatory bowel disease and related conditions, comprising:

an effective and stable dosage suspension of substantially pure 5-ASA contained within a substantially oxygen-free liquid carrier medium, said liquid carrier medium having a material avoidance of antioxidants for said 5-ASA;

at least one application bottle containing said effective dosage suspension;

a sealed, substantially oxygen-free barrier package containing therein said at least one application bottle containing said effective dosage suspension, and an oxygen scavenger; and

said barrier package sufficient to prevent migration of oxygen thereinto and to said dosage suspension upon prolonged storage.

2. The packaged enema of claim 1 , wherein said sealed, substantially oxygen-free barrier package comprises a pouch.

3. The packaged enema of claim 1 , wherein said at least one application bottle contained within a sealed oxygen barrier pouch is of sufficient flexibility to facilitate squeeze dispensing of the contents thereof.

4. The packaged enema of claim 1 , wherein said oxygen scavenger is contained within said oxygen barrier package.

5. The packaged enema of claim 1 , wherein said oxygen scavenger is contained within a sachet.

6. The packaged enema of claim 1 , wherein said application bottle is formed from a malleable polymer.

7. The packaged enema of claim 1 , wherein said oxygen barrier package comprises a laminate comprising polyester/aluminum foil/linear low density polyethylene.

8. The packaged enema of claim 7 , wherein said laminate further comprises at least one compatible adhesive.

9. The packaged enema of claim 1 , wherein said oxygen scavenger is disposed within said sealed substantially oxygen-free barrier package in substantially isolated disposition with regard to said stable dosage suspension.

10. The packaged enema of claim 1 , wherein said oxygen scavenger is disposed within said sealed substantially oxygen-free barrier package in substantially communicating disposition with regard to said stable dosage suspension.

11. The packaged enema of claim 1 , wherein said effective dosage amount is approximately 1 g. to approximately 4 g. of 5-ASA disposed within approximately 20 to approximately 60 ml of said liquid carrier medium.

12. The packaged enema of claim 1 , wherein said liquid carrier medium comprises potassium acetate, xanthan gum, carbomer, sodium benzoate, edentate disodium and purified water.

13. The packaged enema of claim 1 , wherein said package contains a substantially inert gas.

14. The packaged enema of claim 13 , wherein said substantially inert gas comprises nitrogen.

15. The packaged enema of claim 1 , wherein said application bottle contains a substantially inert gas.

16. The packaged enema of claim 15 , wherein said substantially inert gas comprises nitrogen.

17. The packaged enema of claim 1 , wherein said effective dosage has a pH of approximately 3 to approximately 5.

18. The packaged enema of claim 1 , wherein said barrier package is further sufficient to prevent discoloration of said dosage suspension upon prolonged storage.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 7, 2010
From: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
To: ALAVEN PHARMACEUTICAL LLC
Reel/Frame 025105/0550 →
THIRD AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Oct 15, 2009
From: ALAVEN PHARMACEUTICAL LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 023379/0789 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2009
From: VENKATARAMAN, BALA; BROWN, LINDSEY; PATEL, DAXA
To: ALAVEN PHARMACEUTICAL, LLC
Reel/Frame 022938/0735 →
SECOND AMENDED & RESTATED PATENT SECURITY AGREEMENT Recorded Dec 16, 2008
From: ALAVEN PHARMACEUTICAL LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 021993/0146 →
AMENDED & RESTATED PATENT SECURITY AGREEMENT Recorded Mar 25, 2008
From: ALAVEN PHARMACEUTICAL, LLC
To: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT
Reel/Frame 020724/0843 →